Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2018 · 10-Q
Revenue$15.20M$15.20M+33.8% vs Q3 2017 Net Income-$94.66M-$94.66MN/M vs Q3 2017 EPS Diluted-$1.63-$1.63N/M vs Q3 2017 Operating Income-$99,162,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$66,979,000N/M Margins · derivedOperating margin-652.5%+43.2 pt vs Q3 2017
Net margin-622.9%+56.3 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 1, 2018 · 32 d after period end